A Phase 2, Multicenter, Open label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First Line Treatment (CodeBreaK 201)
For more information about the trial above please contact the study team:
Principal Investigator, Mariam Alexander, at firstname.lastname@example.org.
Study Coordinator, Alexandra Leitner, at email@example.com, or please call +1 843-792-1507.
Trial opened at the following institutions: Medical University of South Carolina